Shares of ImmunityBio Inc. traded lower in premarket activity on Tuesday, March 3, 2026, retreating from a significant gain posted in the previous session. The stock was indicated down approximately 1.4% to $10.29, following a 6.75% advance on Monday that saw it close at $10.44. This volatility comes ahead of a scheduled conference call where the biopharmaceutical company will provide a business update and review its full-year financial results.
Market Context and Investor Focus
The premarket weakness aligns with a broader risk-off sentiment among investors Tuesday morning, with U.S. stock index futures pointing to a lower open. Such conditions often disproportionately affect smaller biotechnology stocks like ImmunityBio. Traders and investors are intently focused on the upcoming call, scheduled for 4:30 p.m. Eastern Time, which is expected to provide critical updates that could reset near-term expectations for the company.
Key areas of focus include the commercial traction for its lead therapy ANKTIVA, the company's cash utilization and runway, and the next steps in its clinical and regulatory pipeline. The stock has experienced extreme volatility in recent sessions and remains up more than 400% for the year to date, underscoring the high stakes of the pending update.
Recent Financial and Operational Highlights
In a Securities and Exchange Commission filing last week, ImmunityBio disclosed preliminary financial figures for the full year ended December 31, 2025. The company reported approximately $113 million in net product revenue for ANKTIVA. Furthermore, it ended the fiscal year with a consolidated cash position of $242.8 million, comprising cash, cash equivalents, and marketable securities.
Executive Chairman Dr. Patrick Soon-Shiong highlighted the company's rapid commercial expansion, noting that in under two years since the initial U.S. Food and Drug Administration (FDA) approval, ImmunityBio has established a commercial footprint spanning 33 countries.
ANKTIVA's Profile and Competitive Landscape
ANKTIVA (also known as N-803) is an immunotherapy approved in the United States for use in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certain adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. BCG is a standard bladder-instilled therapy derived from a tuberculosis vaccine.
The treatment landscape for high-risk, BCG-unresponsive bladder cancer is competitive. Other FDA-approved options include Merck & Co.'s Keytruda (pembrolizumab) and Ferring Pharmaceuticals' Adstiladrin (nadofaragene firadenovec), alongside ImmunityBio's ANKTIVA, as noted by urology specialists.
Pipeline Progress and Forward Catalysts
ImmunityBio also provided a pipeline update last week, announcing it had completed enrollment in a Phase 2 clinical trial. The study is evaluating ANKTIVA plus BCG versus BCG alone in patients with BCG-naïve NMIBC. The company flagged interim data showing higher complete-response durability in the combination arm compared to BCG alone.
Dr. Christopher Pieczonka, a principal investigator on the trial, called the interim results "encouraging." ImmunityBio anticipates submitting a Biologics License Application (BLA) for this indication by the fourth quarter of 2026, a catalyst that remains on the distant horizon.
Risks and Trader Scrutiny
ImmunityBio's journey has previously been shaped by regulatory scrutiny of its manufacturing processes. As such, any new commentary on potential supply constraints, slower-than-expected product uptake, or a need for additional financing could pressure a stock that has seen a dramatic run-up. Broader market sell-offs also pose a risk to the highly volatile equity.
During Tuesday's call, market participants will be listening for specific details from management. These include an updated sales cadence for ANKTIVA, commentary on reimbursement dynamics and BCG supply, and whether the company provides any guardrails on its planned spending for 2026. The call represents a pivotal moment for the company to communicate its path to sustainable growth and value creation.
